says Brad Loncar of Loncar Investments Viva Biotech is the fourth largest company in China’s drug discovery services industry, with a 2.6 per cent market share. Photo: Bloomberg Viva Biotech’s hugely …
( read original story …)
Home BUSINESS Investors pile into Viva Biotech’s Hong Kong IPO as they are confident of the R&D services provider’s business model
Categories
Beijing
22°
overcast clouds
humidity: 21%
wind: 1m/s SW
H 22 • L 20
Weather from OpenWeatherMap
Recent Posts
- Japan’s shipbuilders look to consolidation to take on China 06/07/2025
- China snaps up mines around the world in rush to secure resources 06/07/2025
- Japan to Export Used Destroyers to Philippines to Deter China, Yomiuri Reports 06/07/2025
- Hong Kong IPO frenzy sets sights on record HK$250 billion fundraising for 2025 06/07/2025
- China’s abandoned buildings draw urban explorers despite risks 06/07/2025
- China’s New J-20A Stealth Fighter Has Just 1 Mission 06/07/2025
- Indian student shares ahostel tour from China, internet impressed with clean, modern facilities 06/07/2025
- New Zealand golden visa lures potential luxury property buyers from Hong Kong, mainland China 06/07/2025
- For the first time, Xi is missing a China-backed BRICS summit. Why? 06/07/2025
- Trump says US ‘pretty much’ has deal for TikTok, talks with China to begin 06/07/2025
- Certainly not from China: Sachs hinted at which laboratory Covid-19 came from 06/07/2025
- Crypto Weekly: fraud ring dismantled and a sino-US stablecoin race 06/07/2025